# Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
Canonical URL: https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-the-initiation-of-the-phase-1b-program-for-nxp900
Ticker: NVCT
Company: Nuvectis Pharma
Source: Nuvectis Pharma
Published: 2025-08-11 16:30 EST
Original Source URL: https://www.pressviewer.com
## Summary

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p> </p> <ul><li style="text-align:left;">The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers 

## Article Body
The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC whose cancers developed resistance to these treatments
<br...
## Recent Company News
- 2025-09-04 07:30 EST — [Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-to-participate-at-the-h-c-wainwright-27th-annual-global-investment-conference) — Source: Nuvectis Pharma
- 2025-08-11 16:30 EST — [Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-the-initiation-of-the-phase-1b-program-for-nxp900) — Source: Nuvectis Pharma
- 2025-08-05 07:30 EST — [Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-inc-reports-second-quarter-2025-financial-results-and-business-highlights) — Source: Nuvectis Pharma
- 2025-07-31 07:45 EST — [Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-provides-final-clinical-data-update-from-the-nxp800-phase-1b-study-in-ovarian-cancer-and-reports-completion-of-the-nxp900-phase-1a-dose-escalation-study) — Source: Nuvectis Pharma
- 2025-07-08 08:00 EST — [Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-successful-completion-of-a-drug-drug-interaction-study-in-healthy-volunteers-supporting-nxp900-s-potential-as-a-combination-partner-with-leading-therapies) — Source: Nuvectis Pharma
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)